Scribd
Upload
18 views1 page

Formula 82M Efficacy in Hair Loss Treatment

The document contains a collection of studies and clinical trials related to the efficacy of various treatments for androgenetic alopecia and hair growth, including minoxidil and bimatoprost. It highlights findings on the effectiveness of these treatments in both men and women, as well as their safety profiles. The document also references numerous PubMed articles and clinical trials that support these findings.

Uploaded by

arpan
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
18 views1 page

Formula 82M Efficacy in Hair Loss Treatment

The document contains a collection of studies and clinical trials related to the efficacy of various treatments for androgenetic alopecia and hair growth, including minoxidil and bimatoprost. It highlights findings on the effectiveness of these treatments in both men and women, as well as their safety profiles. The document also references numerous PubMed articles and clinical trials that support these findings.

Uploaded by

arpan
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

Faculty Opinions Faculty Reviews 2022 11:(1)

human cytosolic sulfotransferases. Chem Biol Interact. 1998; 109(1–3): 53–67. randomized, double-blind, split-face comparative study. J Dermatol. 2012;
PubMed Abstract | Publisher Full Text 39(10): 865–6.
69. Goren A, Castano JA, McCoy J, et al.: Novel enzymatic assay predicts minoxidil PubMed Abstract | Publisher Full Text
response in the treatment of androgenetic alopecia. Dermatol Ther. 2014; 27(3): 90. Elias MJ, Weiss J, Weiss E: Bimatoprost ophthalmic solution 0.03% for eyebrow
171–3. growth. Dermatol Surg. 2011; 37(7): 1057–9.
PubMed Abstract | Publisher Full Text PubMed Abstract | Publisher Full Text
70. Roberts J, Desai N, McCoy J, et al.: Sulfotransferase activity in plucked hair 91. Tauchi M, Fuchs TA, Kellenberger AJ, et al.: Characterization of an in vivo
follicles predicts response to topical minoxidil in the treatment of female model for the study of eyelash biology and trichomegaly: Mouse eyelash
androgenetic alopecia. Dermatol Ther. 2014; 27(4): 252–4. morphology, development, growth cycle, and anagen prolongation by
PubMed Abstract | Publisher Full Text bimatoprost. Br J Dermatol. 2010; 162(6): 1186–97.
71. Goren A, Sharma A, Dhurat R, et al.: Low-dose daily aspirin reduces topical PubMed Abstract | Publisher Full Text
minoxidil efficacy in androgenetic alopecia patients. Dermatol Ther. 2018; 92. Cohen JL: Enhancing the growth of natural eyelashes: The mechanism of
31(6): e12741. bimatoprost-induced eyelash growth. Dermatol Surg. 2010; 36(9): 1361–71.
PubMed Abstract | Publisher Full Text PubMed Abstract | Publisher Full Text
72. Olsen EA, Dunlap FE, Funicella T, et al.: A randomized clinical trial of 5% 93. Law SK: Bimatoprost in the treatment of eyelash hypotrichosis. Clin
topical minoxidil versus 2% topical minoxidil and placebo in the treatment Ophthalmol. 2010; 4: 349–58.
of androgenetic alopecia in men. J Am Acad Dermatol. 2002; 47(3): 377–85. PubMed Abstract | Publisher Full Text | Free Full Text
PubMed Abstract | Publisher Full Text 94. Allergan: A Safety and Efficacy Study of Bimatoprost in Men With Androgenic
73. Olsen EA, Whiting D, Bergfeld W, et al.: A multicenter, randomized, placebo- Alopecia (AGA). In: [Link]. [Cited 2021, May 24].
controlled, double-blind clinical trial of a novel formulation of 5% minoxidil Reference Source
topical foam versus placebo in the treatment of androgenetic alopecia in men. 95. Allergan: Safety and Efficacy Study of Bimatoprost in the Treatment of Men
J Am Acad Dermatol. 2007; 57(5): 767–74. with Androgenic Alopecia. In [Link]. [Cited 2021, May 24].
PubMed Abstract | Publisher Full Text Reference Source
74. McCoy J, Goren A, Kovacevic M, et al.: Minoxidil dose response study in 96. Allergen: Safety and Efficacy Study of Bimatoprost in the Treatment of Women
female pattern hair loss patients determined to be non-responders to 5% with Female Pattern Hair Loss. In: [Link]. [Cited 2021, May 29].
topical minoxidil. J Biol Regul Homeost Agents. 2016; 30(4): 1153–5. Reference Source
PubMed Abstract | Faculty Opinions Recommendation 97. Toris CB, Gulati V: The biology, pathology and therapeutic use of
75. Goren A, Naccarato T: Minoxidil in the treatment of androgenetic alopecia. prostaglandins in the eye. Clin Lipidol. 2011; 6(5): 577–91.
Dermatol Ther. 2018; 31(5): e12686. Reference Source
PubMed Abstract | Publisher Full Text 98. Xu XG, Chen HD: Prostanoids and Hair Follicles: Implications for Therapy of
76. Sinclair RD: Female pattern hair loss: A pilot study investigating combination Hair Disorders. Acta Derm Venereol. 2018; 98(3): 318–23.
therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018; PubMed Abstract | Publisher Full Text
57(1): 104–9. 99. Blume-Peytavi U, Lönnfors S, Hillmann K, et al.: A randomized double-blind
PubMed Abstract | Publisher Full Text placebo-controlled pilot study to assess the efficacy of a 24-week topical
77. Lueangarun S, Panchaprateep R, Tempark T, et al.: Efficacy and safety of oral treatment by latanoprost 0.1% on hair growth and pigmentation in healthy
minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012; 66(5):
J Am Acad Dermatol. 2015; 72(5): AB113. 794–800.
Publisher Full Text PubMed Abstract | Publisher Full Text
78. Ramos PM, Sinclair RD, Kasprzak M, et al.: Minoxidil 1 mg oral versus minoxidil 100. Choi YM, Diehl J, Levins PC: Promising alternative clinical uses of
5% topical solution for the treatment of female-pattern hair loss: A randomized prostaglandin F2α analogs: Beyond the eyelashes. J Am Acad Dermatol. 2015;
clinical trial. J Am Acad Dermatol. 2020; 82(1): 252–3. 72(4): 712–6.
PubMed Abstract | Publisher Full Text PubMed Abstract | Publisher Full Text

79. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al.: Safety of low-dose 101. Zaky MS, Abo Khodeir H, Ahmed HA, et al.: Therapeutic implications of
oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad topical cetirizine 1% in treatment of male androgenetic alopecia: A case-
Dermatol. 2021; 84(6): 1644–51. controlled study. J Cosmet Dermatol. 2021; 20(4): 1154–9.
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation
80. Khidhir KG, Woodward DF, Farjo NP, et al.: The prostamide-related glaucoma 102. Rossi A, Campo D, Fortuna MC, et al.: A preliminary study on topical cetirizine
therapy, bimatoprost, offers a novel approach for treating scalp alopecias. in the therapeutic management of androgenetic alopecia. J Dermatolog Treat.
FASEB J. 2013; 27(2): 557–67. 2018; 29(2): 149–51.
PubMed Abstract | Publisher Full Text | Free Full Text PubMed Abstract | Publisher Full Text
81. Johnstone MA, Albert DM: Prostaglandin-Induced Hair Growth. Surv Ophthalmol. 103. Farid SF: Topical Cetirizine in Androgenetic Alopecia in Females. In:
2002; 47 Suppl 1: S185–S202. [Link] [Cited 2021, August 16].
PubMed Abstract | Publisher Full Text Reference Source

82. Garza LA, Liu Y, Yang Z, et al.: Prostaglandin D2 inhibits hair growth and is 104. Ibrahim RA: Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of
elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012; Androgenetic Alopecia. [Link] [Cited 2021, August 16].
4(126): 126ra34. Reference Source
PubMed Abstract | Publisher Full Text | Free Full Text | 105. Mecklenburg L, Tobin DJ, Müller-Röver S, et al.: Active hair growth (anagen) is
Faculty Opinions Recommendation associated with angiogenesis. J Invest Dermatol. 2000; 114(5): 909–16.
83. Villarreal-Villarreal CD, Sinclair RD, Martínez-Jacobo L, et al.: Prostaglandins PubMed Abstract | Publisher Full Text
in androgenetic alopecia in 12 men and four female. J Eur Acad Dermatol 106. Semalty M, Semalty A, Joshi GP, et al.: Hair growth and rejuvenation: An
Venereol. 2019; 33(5): e214–e215. overview. J Dermatolog Treat. 2011; 22(3): 123–32.
PubMed Abstract | Publisher Full Text PubMed Abstract | Publisher Full Text
84. Barrón-Hernández YL, Tosti A: Bimatoprost for the treatment of eyelash, 107. Kwon OS, Han JH, Yoo HG, et al.: Human hair growth enhancement in vitro by
eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017; 26(4): 515–22. green tea epigallocatechin-3-gallate (EGCG). Phytomedicine. 2007; 14(7–8):
PubMed Abstract | Publisher Full Text 551–5.
85. Yoelin S, Walt JG, Earl M: Safety, effectiveness, and subjective experience PubMed Abstract | Publisher Full Text
with topical bimatoprost 0.03% for eyelash growth. Dermatol Surg. 2010; 36(5): 108. Adhirajan N, Ravi Kumar T, Shanmugasundaram N, et al.: In vivo and in vitro
638–49. evaluation of hair growth potential of Hibiscus rosa-sinensis Linn.
PubMed Abstract | Publisher Full Text J Ethnopharmacol. 2003; 88(2–3): 235–9.
86. Beer KR, Julius H, Dunn M, Wilson F, et al.: Treatment of eyebrow hypotrichosis PubMed Abstract | Publisher Full Text
using bimatoprost: A randomized, double-blind, vehicle-controlled pilot study. 109. Fertig RM, Gamret AC, Cervantes J, et al.: Microneedling for the treatment of
Dermatol Surg. 2013; 39(7): 1079–87. hair loss? J Eur Acad Dermatol Venereol. 2018; 32(4): 564–9.
PubMed Abstract | Publisher Full Text PubMed Abstract | Publisher Full Text
87. Carruthers J, Beer K, Carruthers A, et al.: Bimatoprost 0.03% for the Treatment 110. Lee YB, Eun YS, Lee JH, et al.: Effects of topical application of growth factors
of Eyebrow Hypotrichosis. Dermatol Surg. 2016; 42(5): 608–17. followed by microneedle therapy in women with female pattern hair loss: A
PubMed Abstract | Publisher Full Text | Free Full Text pilot study. J Dermatol. 2013; 40(1): 81–3.
88. Schweiger ES, Pinchover L, Bernstein RM: Topical bimatoprost for the treatment PubMed Abstract | Publisher Full Text
of eyebrow hypotrichosis. J Drugs Dermatol. 2012; 11(1): 106–8. 111. Zarei M, Wikramanayake TC, Falto-Aizpurua L, et al.: Low level laser therapy and
PubMed Abstract hair regrowth: An evidence-based review. Lasers Med Sci. 2016; 31(2): 363–71.
89. Suwanchatchai W, Tanglertsampan C, Pengsalae N, et al.: Efficacy and safety PubMed Abstract | Publisher Full Text
of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: A 112. Chung PS, Kim YC, Chung MS, et al.: The effect of low-power laser on the

Common questions

Powered by AI

Growth factors and microneedle therapy have been used in combination to treat female pattern hair loss. Studies show that the topical application of growth factors followed by microneedle therapy can stimulate hair growth by enhancing skin penetration and promoting angiogenesis, reflecting promising results in experimental studies .

Enzymatic activity in hair follicles, particularly sulfotransferase activity, is predictive of a patient's response to minoxidil. Higher sulfotransferase activity in plucked hair follicles indicates a better response to topical minoxidil treatments in androgenetic alopecia, suggesting that individual variations in enzyme levels can affect treatment efficacy .

Prostaglandin D2 has been found to inhibit hair growth and is elevated in the bald scalps of men with androgenetic alopecia. This suggests that targeting prostaglandin D2 pathways could be a potential therapeutic strategy for treating this type of hair loss .

Bimatoprost, originally used for glaucoma, is effective in promoting hair growth in conditions like eyelash hypotrichosis and also shows promise in scalp alopecia, including androgenetic alopecia. It is generally safe, but potential side effects include eye irritation and pigmentation changes. Its efficacy varies with application and formulation .

Angiogenesis is crucial during the anagen phase for supplying nutrients and oxygen to rapidly growing hair follicles. Understanding its role helps in developing therapies that promote vascular growth to prevent or slow hair loss, offering potential treatments for conditions where follicular support is lacking .

Recent studies suggest that while both oral and topical minoxidil are effective, oral minoxidil at low doses has been shown to have promising results and a good safety profile. However, individual response can vary, and thus the route of administration should be tailored to the patient's needs and response .

Cetirizine, an antihistamine, may offer an alternative approach by acting as an anti-inflammatory agent, which could complement traditional androgenetic alopecia treatments like minoxidil. Preliminary studies suggest it could affect hair growth by modulating inflammatory pathways .

LLLT shows promise due to its ability to stimulate follicular cell proliferation and increase hair density without significant side effects. Compared to treatments like microneedling and topical formulations, LLLT offers a non-invasive and effective alternative, but individual response varies. Overall, current evidence supports its use in combination therapy for enhanced results .

Green tea EGCG enhances human hair growth in vitro by stimulating keratinocyte proliferation. This suggests potential therapeutic uses, such as incorporating EGCG into topical treatments for hair growth due to its ability to promote anagen (active growth) phase in hair follicles .

Human cytosolic sulfotransferases (SULTs) influence drug metabolism by catalyzing the sulfonation of small molecules, which increases their solubility and facilitates excretion. This process is crucial for the detoxification of drugs and xenobiotics but can also affect hormone regulation and neurotransmitter metabolism, thereby impacting overall human health .

You might also like